<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912143</url>
  </required_header>
  <id_info>
    <org_study_id>GEPHARD</org_study_id>
    <secondary_id>DRKS00011101</secondary_id>
    <nct_id>NCT02912143</nct_id>
  </id_info>
  <brief_title>German Pediatric Hemophilia Research Database</brief_title>
  <acronym>GEPHARD</acronym>
  <official_title>German Pediatric Hemophilia Research Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Committee of the German Thrombosis and Hemostasis Research Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Thrombosis and Hemostasis Research Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The German Pediatric Hemophilia Research Database will collect data on the prophylactic and
      therapeutic use of factor concentrates, complications, outcome measures (joint scores, QoL)
      and living circumstances in newly diagnosed children with hemophilia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with antibody developement to exogenous clotting factors (&gt;0.5 BU)</measure>
    <time_frame>5 years</time_frame>
    <description>Blood Test: measurement in Bethesda Units, positive according to local standards, for most labs &gt; 0.5 BU</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <condition>Children</condition>
  <condition>Drug Specific Antibodies</condition>
  <arm_group>
    <arm_group_label>newly diagnosed children with hemophilia</arm_group_label>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>documentation only</intervention_name>
    <arm_group_label>newly diagnosed children with hemophilia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All children between 0 and 18 yrs diagnosed with hemophilia A or B (FVIII/FIX &lt; 1% to 25%)
        from 01.01.2017.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemophilia A or B

          -  FVIII/FIX &lt;1% to 25%

          -  informed consent

        Exclusion Criteria:

          -  no consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Bidlingmaier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hemophilia Center, Dr. v. Hauner Children's Hospital, University of Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Bidlingmaier, MD</last_name>
    <phone>+498944005</phone>
    <phone_ext>2830</phone_ext>
    <email>Christoph.bidlingmaier@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph KÃ¶nigs, PhD</last_name>
    <phone>+496963018</phone>
    <phone_ext>3030</phone_ext>
    <email>christoph.koenigs@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. v. hauner Children's Hospital</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Bidlingmaier, MD</last_name>
      <phone>004989440052830</phone>
      <email>christoph.bidlingmaier@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Christoph Bidlingmaier</investigator_full_name>
    <investigator_title>Consultant Pediatric Hemophilia Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Patient data will not be shared outside specified collaborating studies (none yet)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

